University Hospital Centre Zagreb have successfully finalized two evaluation studies of Hemcheck’s products at the Department of Laboratory Diagnostics. These formal evaluations preliminary results confirm the conclusions from earlier studies that the performance of Hemcheck’s products is very high.

The first study evaluated the presence of hemolysis in nearly 600 arterial and venous blood gas samples using Hemcheck’s system after routine blood gas analysis had been performed. The results were then compared to the laboratory’s clinical chemistry analyser results as the reference method.

The second study evaluated more than 300 venous blood samples collected in vacuum tubes in routine care, where the results were also compared to the laboratory’s reference method.

The preliminary conclusions are that the system has good performance and a very strong level of agreement with the laboratory reference method, while being easy to use, fast and mobile.

– This is positive news as it gives additional evidence on the performance and the value of our system. We look forward to continuing discussions with University Hospital Centre Zagreb and to disseminate the results at relevant scientific forums, says Joen Averstad, CEO of Hemcheck.

– I am very satisfied with the studies and the preliminary results are highly interesting. The Hemcheck system showed good performance and I believe it can be an important tool for rapid detection of hemolysis at the point of care, says Ivana Baršić Lapić, European Specialist in Laboratory Medicine (EuSpLM) and responsible for the evaluation study.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About University Hospital Centre Zagreb

University Hospital Centre Zagreb is the largest health institution in Croatia, considering the number and diversity of health services it provides. The hospital has several sites and has around 2000 beds in total. It is the base for 70 referral centres of the Ministry of Health in Croatia.

Read more at: https://www.kbc-zagreb.hr/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolyzed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolyzed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.